Ultrasensitive Screening Platform Detects Pathogenic Bacteria

These genetic probes are introduced alongside material taken from the sample being tested. A magnetic process isolates segments from the sample that match the probe, and these segments are then analyzed using high-throughput sequencing.

The use of the 70-hour BacCapSeq test resulted in an up to 1,000-fold increase in bacterial reads from blood samples and lowered the limit of detection by one to two orders of magnitude compared to conventional unbiased high-throughput sequencing,
At this level of sensitivity, the test detected not only the presence of AMR genes but also biomarkers for AMR that included both constitutive and differentially expressed transcripts.

"Microbiological intelligence must be an integral component of precision medicine," said senior author Dr. W. Ian Lipkin, professor of epidemiology at Columbia University. "Accurate, early differential diagnosis of infectious diseases and knowledge of drug sensitivity profiles will reduce mortality, morbidity, and health care costs."

The BacCapSeq diagnostic platform was described in the October 23, 2018, online edition of the journal mBio.

Related Links:
Columbia University